Kenvue Inc. (KVUE)
| Market Cap | 41.57B |
| Revenue (ttm) | 15.30B |
| Net Income (ttm) | 1.06B |
| Shares Out | 1.92B |
| EPS (ttm) | 0.55 |
| PE Ratio | 39.26 |
| Forward PE | 18.64 |
| Dividend | $0.82 (3.79%) |
| Ex-Dividend Date | May 14, 2025 |
| Volume | 16,315,093 |
| Open | 21.65 |
| Previous Close | 21.45 |
| Day's Range | 21.44 - 22.03 |
| 52-Week Range | 17.67 - 25.17 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 25.33 (+17.0%) |
| Earnings Date | Aug 5, 2025 |
About KVUE
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other... [Read more]
Financial Performance
In 2024, Kenvue's revenue was $15.46 billion, an increase of 0.07% compared to the previous year's $15.44 billion. Earnings were $1.03 billion, a decrease of -38.10%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price forecast is $25.33, which is an increase of 17.00% from the latest price.
News
Kenvue mulls sale of some skin health and beauty brands, sources say
Kenvue is exploring the sale of some of its skin health and beauty brands, four people familiar with the matter said on Thursday, as the consumer health firm prunes an underperforming business segment...
INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Kenvue Inc. and Encourages Long-Term Kenvue Investors to Contact the Firm - KVUE
PHILADELPHIA, PA / ACCESS Newswire / June 9, 2025 / Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Kenvue Inc. (NYSE:KVUE) on behalf of the com...
Kenvue: Steady Consumer Health Play; Initiate With 'Buy'
I initiate Kenvue with a 'Buy' rating and a $26 fair value, citing its iconic brands and steady dividend appeal. Kenvue's global operations, diversified product lines, and strong R&D enable resilience...
June's Dividend Kings: 3 Ideal Buys In 25 "Safer" Dogs
Most Dividend Kings are currently overpriced, but six offer fair value where annual dividends from $1,000 invested exceed their share price. Three top-yield Dividend Kings—Altria, Northwest Natural, a...
Benadryl, Band-Aid parent says tariffs and late allergy season are hurting its business
Kenvue Chief Executive Thibaut Mongon said the consumer continues to be under pressure.
Kenvue Debuts on Fortune 500 List
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for t...
Kenvue Announces Participation in Deutsche Bank's dbAccess Global Consumer Conference
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced the Company's participation in Deutsche Bank...
69 May Aristocrats: Buy 1 Of 38 "Safer" Dividend Dogs
Many S&P 500 Dividend Aristocrats remain overvalued, but select high-yield 'Dogs' like Realty Income and Amcor offer attractive entry points for income investors. Analyst forecasts suggest the top ten...
Moody's U.S. Debt Downgrade: Stocks Poised To Benefit
Corporations play a vital and often benevolent role in capitalist societies, supporting economic growth and innovation with more conservative balance sheets than their governments. Microsoft, Apple an...
Third Point details stakes in U.S. Steel, Kenvue in filing
Billionaire investor Daniel Loeb's hedge fund Third Point on Thursday detailed the size of its stakes in U.S. Steel and Kenvue , companies that shareholders hope will soon benefit from being bought by...
Everyday Care in Action: Thousands of Kenvue Employees Come Together Across 21 Markets to Help Advance Healthier Communities
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. today announced its global efforts in celebration of Kenvue Cares Week, the company's signature annual volunteer initiative.
Kenvue: First Quarter A Sign Of Challenging Times, But Still A Solid Long-Term Play
Kenvue, a solid dividend-paying stock spun off from Johnson & Johnson, offers long-term upside despite current economic challenges and declining consumer sentiment. Recent earnings showed slight reven...
Kenvue, Inc. (KVUE) Q1 2025 Earnings Call Transcript
Kenvue, Inc. (NYSE:KVUE) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Sofya Tsinis - Head of Investor Relations Thibaut Mongon - Chief Executive Officer and Director P...
Kenvue Boosts 2025 Sales Growth View
The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial officer and boosted its sales-growth projection for the year, w...
Listerine, Tylenol Maker Kenvue Tops Estimates, Lifts Sales Outlook
Shares of Kenvue (KVUE) rose in premarket trading Thursday after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter results better than analysts' estimates.
Kenvue first-quarter results beat estimates on strength in self care unit
Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday, as strong demand for its self-care products including cough and cold medicines Tylenol and Benadryl helped offset a...
Kenvue Reports First Quarter 2025 Results
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the first quarter ended March 30, 2025. “In Q1, our teams executed our plans while continuing to navigate ...
Kenvue Announces Chief Financial Officer Transition
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for ove...
Buy 3 "Safer" Dividend Kings Of 25 From May's 55
The May collection of Dividend Kings grew to 55, with Automatic Data Processing and RLI Corporation joining, despite two companies dropping off for not increasing dividends. Six top-yield Dividend Kin...
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed...
Loeb's Third Point builds stake in Band-Aid maker Kenvue
Billionaire investor Daniel Loeb's hedge fund Third Point is building a stake in Kenvue , sources familiar with the matter said on Friday, as some investors are pushing for strategic changes at the co...
Kenvue to Announce First Quarter 2025 Results on May 8, 2025
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025. The company will host a conference call and webcast at...
Two Stocks To Consider During Market Unrest To Provide Income Stability
Investors should remain calm amid market volatility and consider buying during price dips, with 2025 expected to see more turbulence. Kenvue's strong brand portfolio and solid liquidity offer price st...
Kenvue Declares Quarterly Cash Dividend
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on its common stock. This quarterly dividend i...
Kenvue Announces 5-Year Collaboration with Microsoft to Transform Digital Operations
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue announced a five-year collaboration with Microsoft to transform digital operations through Artificial Intelligence (AI) technologies.